These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35646455)

  • 1. Apremilast Survival and Reasons for Discontinuation in Psoriasis: Five-Year Experience From a Greek Tertiary Care Centre.
    Sotiriou E; Tsentemeidou A; Sideris N; Lallas A; Kougkas N; Ioannides D; Vakirlis E
    Dermatol Pract Concept; 2022 May; 12(2):e2022076. PubMed ID: 35646455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.
    Ohata C; Ohyama B; Kuwahara F; Katayama E; Nakama T
    J Dermatolog Treat; 2019 Jun; 30(4):383-386. PubMed ID: 30221571
    [No Abstract]   [Full Text] [Related]  

  • 3. Is apremilast for psoriasis as effective and safe as reported in clinical trials? Five-year experience from a Greek tertiary hospital: long-term real-life efficacy and safety of apremilast in Greece.
    Sotiriou E; Tsentemeidou A; Vakirlis E; Sideris N; Bakirtzi K; Papadimitriou I; Lallas A; Ioannides D
    Clin Exp Dermatol; 2021 Dec; 46(8):1542-1544. PubMed ID: 33811368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
    Sbidian E; Billionnet C; Weill A; Maura G; Mezzarobba M
    Br J Dermatol; 2020 Mar; 182(3):690-697. PubMed ID: 31021438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-year drug survival of apremilast in patients with psoriasis.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Kuwahara A; Ohtsuki M
    J Dermatol; 2023 Jul; 50(7):960-963. PubMed ID: 36938674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
    Distel J; Cazzaniga S; Seyed Jafari SM; Emelianov V; Schlapbach C; Yawalkar N; Heidemeyer K
    Dermatology; 2022; 238(2):267-275. PubMed ID: 34091455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Del Alcázar E; Suárez-Pérez JA; Armesto S; Rivera R; Herrera-Acosta E; Herranz P; Martín I; Montesinos E; Hospital M; Vilarrasa E; Ferran M; Ruiz-Villaverde R; Sahuquillo-Torralba A; Ruiz-Genao DP; Pérez-Barrio S; Muñoz C; Llamas M; Valentí F; Mitxelena MJ; López-Ferrer A; Carretero G; Vidal D; Mollet J; Belinchón I; Carrascosa JM
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2821-2829. PubMed ID: 32271966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting.
    Kapniari E; Dalamaga M; Papadavid E
    Dermatol Ther; 2020 Nov; 33(6):e14168. PubMed ID: 32779293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug survival of apremilast in a real-world setting.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2019 Jul; 46(7):615-617. PubMed ID: 31180150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apremilast in psoriasis - a prospective real-world study.
    Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
    Kt S; Thakur V; Narang T; Dogra S; Handa S
    Am J Clin Dermatol; 2021 May; 22(3):415-423. PubMed ID: 33712987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
    Radi G; Campanati A; Diotallevi F; Rizzetto G; Martina E; Bobyr I; Giannoni M; Offidani A
    Dermatol Ther; 2021 Nov; 34(6):e15179. PubMed ID: 34704350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
    Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
    Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis.
    Lunder T; Zorko MS; Kolar NK; Suhodolcan AB; Marovt M; Leskovec NK; Marko PB
    Int J Dermatol; 2019 Jun; 58(6):631-641. PubMed ID: 30973647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.
    Graier T; Weger W; Sator PG; Salmhofer W; Gruber B; Jonak C; Kölli C; Schütz-Bergmayr M; Vujic I; Ratzinger G; Häring N; Painsi C; Prillinger K; Mlynek A; Skvara H; Trattner H; Tanew A; Lichem R; Ellersdorfer C; Legat F; Gruber-Wackernagel A; Hofer A; Schmiedberger E; Hoetzenecker W; Müllegger R; Saxinger W; Quehenberger F; Wolf P
    JAAD Int; 2021 Mar; 2():62-75. PubMed ID: 34409355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study.
    Augustin M; Kleyn CE; Conrad C; Sator PG; Ståhle M; Eyerich K; Radtke MA; Bundy C; Mellars L; Greggio C; Cordey M; Koscielny V; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):123-134. PubMed ID: 32279378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
    Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.